The role of cytoreductive surgery in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline

J Neurooncol. 2014 Jul;118(3):479-88. doi: 10.1007/s11060-013-1336-7. Epub 2014 Apr 23.

Abstract

Question: Should patients with previously diagnosed malignant glioma who are suspected of experiencing progression of the neoplasm process undergo repeat open surgical resection?

Target population: These recommendations apply to adults with previously diagnosed malignant glioma who are suspected of experiencing progression of the neoplastic process and are amenable to surgical resection.

Recommendations level ii: Repeat cytoreductive surgery is recommended in symptomatic patients with locally recurrent or progressive malignant glioma. The median survival in these patient diagnosed with glioblastoma is expected to range from 6 to 17 months following a second procedure. It is recommended that the following preoperative factors be considered when evaluating a patient for repeat operation: location of recurrence in eloquent/critical brain regions, Karnofsky Performance Status and tumor volume.

Publication types

  • Practice Guideline
  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Brain Neoplasms / pathology
  • Brain Neoplasms / surgery*
  • Disease Progression
  • Evidence-Based Medicine
  • Glioblastoma / pathology
  • Glioblastoma / surgery*
  • Humans
  • Neoplasm Recurrence, Local
  • Neurosurgical Procedures / methods*
  • Tumor Burden